Myriam Susana Levy

Myriam Susana Levy

Auto-generated profile, based on publicly available information

Myriam Susana Levy

The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in Trends in Biotechnology
Verified
Journal Article
Closed access
MLM.Susana Levy
M.Susana Levy
RORonan D O’kennedy
Ronan D O’kennedy
PAParviz Ayazi-Shamlou
Parviz Ayazi-Shamlou
PDPeter Dunnill
Peter Dunnill

1 May 2006 in Chemical Engineering Science
Verified
Journal Article
Closed access
MMM. Micheletti
M. Micheletti
TBT. Barrett
T. Barrett
SDS.D. Doig
S.D. Doig
FBFrank Baganz
Frank Baganz
MLM.S. Levy
M.S. Levy
GLGary Lye
Gary Lye

1 January 1999 in Bioprocess and Biosystems Engineering
Verified
Journal Article
Closed access
PDF file
MLM. S. Levy
M. S. Levy
ICI. J. Collins
I. J. Collins
SYS. S. Yim
S. S. Yim
JWJohn M. Ward
John M. Ward
NTN. Titchener-Hooker
N. Titchener-Hooker
PDP. Dunnill
P. Dunnill

29 October 2007 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
RIR.S. Islam
R.S. Islam
DTD. Tisi
D. Tisi
MLM.S. Levy
M.S. Levy
GLGary Lye
Gary Lye

8 September 2009 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
TBTimothy A. Barrett
Timothy A. Barrett
AWAndrew Wu
Andrew Wu
Hu ZhangHu Zhang
Hu Zhang
MLM. Susana Levy
M. Susana Levy
GLGary Lye
Gary Lye

1 January 2005 in Biotechnology Progress
Verified
Journal Article
Open access
PDF file
MHMike Hoare
Mike Hoare
MLM. Susana Levy
M. Susana Levy
Daniel G. BracewellDaniel G. Bracewell
Daniel G. Bracewell
SDSteven D. Doig
Steven D. Doig
SKSimyee Kong
Simyee Kong
PDPeter Dunnill
Peter Dunnill
The risk of a pandemic with a virulent form of influenza is acknowledged by the World Health Organization (WHO) and other agencies. Current vaccine production facilities would be unable to meet the global requirement for vaccine. As a possible supplement a DNA vaccine may be appropriate, and bioprocess engineering factors bearing on the use of existing biopharmaceutical and antibiotics plants to produce it are described. This approach addresses the uncertainty of timing of a pandemic that precludes purpose‐built facilities. The strengths and weaknesses of alternative downstream processing routes are analyzed, and several gaps in public domain information are addressed. The conclusion is that such processing would be challenging but feasible.